Studying Fibroblast Activity in Patients With Localized Pancreatic Cancer Undergoing Surgery
Conditions
Pancreatic Cancer
Conditions: official terms
Pancreatic Neoplasms
Conditions: Keywords
adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage I pancreatic cancer, stage II pancreatic cancer
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: protein expression analysis Type: Genetic
Name: western blotting Type: Genetic
Name: immunohistochemistry staining method Type: Other
Name: immunologic technique Type: Other
Name: laboratory biomarker analysis Type: Other
Overall Status
Recruiting
Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research study is assessing fibroblast activity in patients with localized pancreatic cancer undergoing surgery.
Detailed Description
OBJECTIVES:

Primary

- To assess the degree of fibroblast activation protein (FAP) enzymatic activity at the tumor site in patients with localized pancreatic cancer.

Secondary

- To explore correlations between tumor stromal FAP enzymatic activity and stromal α_2-antiplasmin levels.

- To explore correlations between tumor FAP enzymatic activity and plasma dipeptidyl peptidase and plasma α_2-antiplasmin converting enzyme activity as potential surrogates.

OUTLINE: Patients undergo fine-needle aspiration of tumor or suspected mass at baseline. Tumor samples are analyzed by IHC for fibroblast activation protein (FAP) expression, immunocapture assay for ex vivo FAP enzymatic activity, and western analysis for FAP concentrations. Blood samples are collected weekly and analyzed for dipeptidyl peptidase activity by ELISA and α_2-antiplasmin converting enzyme.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Both
Criteria: DISEASE CHARACTERISTICS:

- Biopsy-proven adenocarcinoma of the pancreas or pancreatic mass suspicious for pancreatic cancer

- Localized disease

- Scheduled to undergo a resection or exploration of their pancreatic tumor

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics
Location
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States
Status: Recruiting
Contact: Clinical Trials Office - Fox Chase Cancer Center - Philadelphi - 215-728-4790
Start Date
August 2007
Sponsors
Fox Chase Cancer Center
Source
Fox Chase Cancer Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page